Insights from 2023 ASH Annual Meeting
R

Clinically-Relevant Updates in ALL in Adults

By Insights from 2023 ASH Annual Meeting FEATURING Ryan Cassaday
By Insights from 2023 ASH Annual Meeting FEATURING Ryan Cassaday
228 views
February 20, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:47
Sarah Tasian

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
16:28
Fred Hutchinson Cancer Center

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Feat. R. Cassaday
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis
13:51
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

ALL in Adults: Overview and Recent Advances

Feat. R. Cassaday
11:35
Vanderbilt University Medical Center (VUMC)

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Feat. A. Jallouk
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale
09:42
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…

Feat. M. Al Malki
31:41
MyCancerHaven

Treating Adults With Newly Diagnosed ALL

Feat. R. Vij, A. Patel
13:26
Steven Pavletic

Chronic GvHD: Main Complications After ASCT

22:36
UChicago Medicine

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

Feat. A. Cooper
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
20:18
Stanford Medicine

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Feat. M. Hamilton
37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June